Investigating heart damage caused by cancer treatments using lab-grown heart cells.
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
['FUNDING_OTHER'] · VALA SCIENCES, INC. · NIH-11142333
This study is looking at how some cancer treatments might harm the heart, using special lab-grown heart cells to see how chemotherapy affects heart function, which could help doctors better understand and predict heart problems in cancer survivors.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VALA SCIENCES, INC. (nih funded) |
| Locations | 1 site (SAN DIEGO, UNITED STATES) |
| Trial ID | NIH-11142333 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how certain cancer treatments can lead to heart damage, known as cardiotoxicity. By using lab-grown heart cells derived from induced pluripotent stem cells (iPSCs), the study aims to simulate and measure the effects of chemotherapy on heart function. The approach allows for a more accurate assessment of how these drugs impact heart cells without relying solely on animal models. This could lead to better predictions of heart-related side effects in cancer survivors.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer survivors who have experienced heart issues related to their treatment.
Not a fit: Patients who have not undergone cancer treatment or those without any cardiac concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help develop safer cancer treatments that minimize heart damage for patients.
How similar studies have performed: Other research has shown promise in using lab-grown cells to study drug effects, indicating that this approach could yield valuable insights.
Where this research is happening
SAN DIEGO, UNITED STATES
- VALA SCIENCES, INC. — SAN DIEGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PRICE, JEFFREY H. — VALA SCIENCES, INC.
- Study coordinator: PRICE, JEFFREY H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents